What is Pulmocide?
Pulmocide operates as a specialized biopharmaceutical entity dedicated to the discovery and development of novel therapeutics for respiratory health. The company focuses on high-unmet-need areas, specifically targeting acute and chronic infections that frequently lead to severe clinical complications. By integrating advanced medicinal chemistry with a deep understanding of pulmonary pathology, Pulmocide has established a unique market position as a developer of next-generation inhaled therapies. Its strategic focus on respiratory medicine allows it to address the limitations of current standard-of-care treatments, providing a platform for significant value creation within the life sciences ecosystem.
How much funding has Pulmocide raised?
Pulmocide has raised a total of $149.9M across 3 funding rounds:
Series A
$27.5M
Series B
$30.4M
Series C
$92M
Series A (2013): $27.5M with participation from F-Prime Capital Partners, Imperial Innovations Group plc, Johnson & Johnson Development Corporation, and S.V. Life Sciences
Series B (2017): $30.4M led by Touchstone Innovations plc, F-Prime Capital, S.R. One, JJDC, Inc, Longwood Fund, and S.V. Life Sciences
Series C (2021): $92M supported by Jeito Capital, SR One, Adjuvant Capital, SV Health Investors, and Asahi Kasei Pharma
Key Investors in Pulmocide
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growthstage life sciences companies developing novel therapeutics, leveraging deep sector expertise and operational support.
Johnson & Johnson Development Corporation
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies, providing innovative medicines and surgical products across multiple therapeutic areas.
What's next for Pulmocide?
Looking ahead, the recent capital influx will likely be directed toward the expansion of Pulmocide's clinical trial infrastructure and the acceleration of its lead candidates toward regulatory submission. As the company transitions into a more mature phase of its lifecycle, the focus will shift from early-stage discovery to commercial readiness and strategic partnerships. The involvement of high-caliber life science investors suggests a clear path toward potential exit opportunities or the scaling of internal manufacturing and distribution capabilities. Maintaining this momentum will be essential as the firm seeks to validate its therapeutic efficacy in larger, more diverse patient cohorts, ultimately aiming to redefine the treatment landscape for respiratory tract infections.
See full Pulmocide company page
